703 results on '"Gatell, José"'
Search Results
2. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial
Catalog
Books, media, physical & digital resources
3. Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study
4. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
5. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years : Final 96-Week Results of the NEAT022 Study
6. Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed
7. Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses
8. Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling
9. Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity
10. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
11. Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
12. Left-sided infective endocarditis in patients with liver cirrhosis
13. Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos
14. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
15. Posicionamiento de dolutegravir en el tratamiento de la infección por el VIH
16. Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial
17. Brote epidémico de hepatitis aguda C en pacientes infectados por el virus de la inmunodeficiencia humana
18. Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial
19. Incidence of hypertension and blood pressure changes in persons with human immunodeficiency virus (HIV) at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir : a post-hoc analysis of the 96-week randomised NEAT-022 trial
20. Immunological and virological findings in a patient with exceptional post-treatment control: a case report
21. Eficacia del tratamiento antirretroviral de inicio basado en lopinavir/ritonavir más 2 análogos de nucleósidos/nucleótidos en pacientes infectados por el virus de la inmunodeficiencia humana-1
22. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses
23. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
24. Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial
25. Effect of Vancomycin Minimal Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Endocarditis
26. Structured therapy interruptions (STIs): lessons from a therapeutic strategy
27. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
28. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
29. A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: From nucleocapsid-condensed RNA to Vpr-bridged DNA
30. Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
31. Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs
32. HIV incidence in the Estonian population in 2013 determined using the HIV‐1 limiting antigen avidity assay
33. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
34. Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial
35. Antiretroviral Therapy for HIV: Do Subtypes Matter?
36. HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
37. Lymphoid Tissue Collagen Deposition in HIV-Infected Patients Correlates With the Imbalance Between Matrix Metalloproteinases and Their Inhibitors
38. Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis
39. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
40. A Step Ahead on the HIV Collaboratory
41. Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose-Ranging Study Involving Treatment-Experienced Patients with HIV-1 Infection
42. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
43. Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue
44. Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines
45. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco
46. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study
47. Impact of HIV-1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogue-Based Regimens in Antiretroviral Therapy (ART)-Naive and ART-Experienced Patients
48. Immunological Profile of Heterosexual Highly HIV-Exposed Uninfected Individuals: Predominant Role of CD4 and CD8 T-Cell Activation
49. HIV and Syphilis: When to Perform a Lumbar Puncture
50. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.